更新于：2024-09-25
Dalbavancin Hydrochloride
盐酸达巴万星
更新于：2024-09-25
概要
基本信息
药物类型 化学药 |
别名 dalbavancin、dalbavancin hcl、Dalbavancin powder + [14] |
作用机制 肽聚糖抑制剂、细胞壁抑制剂 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-05-23), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看首次获批时间轴
关联
42
项与 盐酸达巴万星 相关的临床试验Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy
100 项与 盐酸达巴万星 相关的临床结果
登录后查看更多信息
100 项与 盐酸达巴万星 相关的转化医学
登录后查看更多信息
100 项与 盐酸达巴万星 相关的专利（医药）
登录后查看更多信息
743
项与 盐酸达巴万星 相关的文献（医药）2024-11-01ANNALS OF VASCULAR SURGERY
Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus aureus Biofilms on Synthetic and Biological Vascular Grafts
Article
作者: Gil-Sala, Daniel ; Muñoz, Estela ; Gavaldà, Joan ; Fernández-Hidalgo, Nuria ; Tello-Díaz, Cristina ; Gomis, Xavier ; Palau, Marta ; Bellmunt-Montoya, Sergi
BACKGROUND:
Biofilm formation is one of the greatest challenges encountered in vascular graft infections. Our aim is to compare the efficacy of 5 antibiotics against methicillin-susceptible Staphylococcus aureus (MSSA) biofilms on the surface of 4 vascular grafts.
METHODS:
In vitro study of 2 clinical MSSA strains (MSSA2 and MSSA6) and 4 vascular grafts (Dacron, Dacron-silver-triclosan (DST), Omniflow-II, and bovine pericardium). After a 24-hr incubation period, the graft samples were divided into 6 groups: growth control (no treatment), ciprofloxacin 4.5 mg/L, cloxacillin 100 mg/L, dalbavancin 300 mg/L, daptomycin 140 mg/L, and linezolid 20 mg/L. Quantitative cultures were obtained and results expressed as log10 colony-forming units per milliliter (CFU/mL). Analysis of variance was performed to compare biofilm formation between the different groups.
RESULTS:
The mean ± standard deviation MSSA2 count on the growth control Dacron graft was 10.05 ± 0.31 CFU/mL. Antibiotic treatment achieved a mean reduction of 45%; ciprofloxacin was the most effective antibiotic (64%). Baseline MSSA2 counts were very low on the DST (0.50 ± 1.03 CFU/mL) and Omniflow-II (0.33 ± 0.78 CFU/mL) grafts. On the bovine pericardium patch, the count was 9.87 ± 0.50 CFU/mL, but this was reduced by a mean of 45% after antibiotic treatment (61% for ciprofloxacin). The mean MSSA6 count on the growth control Dacron graft was 9.63 ± 0.53 CFU/mL. Antibiotics achieved a mean reduction of 48%, with ciprofloxacin performing best (67% reduction). The baseline MSSA6 count on the DST graft was 8.54 ± 0.73 CFU/mL. Antibiotics reduced biofilm formation by 72%; cloxacillin was the most effective treatment (86%). The MSSA6 count on the untreated Omniflow-II graft was 1.17 ± 1.52 CFU/mL. For the bovine pericardium patch, it was 8.98 ± 0.67 CFU/mL. The mean reduction after antibiotic treatment was 46%, with cloxacillin achieving the greatest reduction (68%).
CONCLUSIONS:
In this in vitro study, ciprofloxacin and cloxacillin performed best at reducing biofilms formed by clinical MSSA strains on the surface of biological and synthetic vascular grafts.
2024-09-19JOURNAL OF PHARMACY PRACTICE
One and Done? An Evaluation of the Clinical Outcomes of Single- and Multi-Dose Dalbavancin Use in the Pediatric Population.
Article
作者: Morrisette, Taylor ; Alghamdi, Shahad ; Maree, Megan B ; Dixon, Terry C ; Thacker, Stephen A
Staphylococcus aureus is a leading cause of invasive bacterial infections in the pediatric population. In general, data surrounding the use of newly approved antimicrobials within children are lacking. Dalbavancin is a long-acting lipoglycopeptide that shows promise for off-label use in adults given its unique pharmacokinetics and in vitro potency against common Gram-positive isolates; however, evidence to supports its use in children is limited. We report the use of dalbavancin in three pediatric cases in patients aged 17 months of age, 3 years of age, and 11 years of age. All infections were caused by S. aureus (66.7% methicillin-resistant S. aureus) representing varied disease, including an osteoarticular infection and catheter-related bloodstream infection. Furthermore, all patients had pediatric infectious diseases involvement. Following the utilization of DAL, high clinical success and low rates of adverse effects were observed with high patients' and parents' satisfaction. While larger, confirmatory real-world studies are needed, our findings support safe off-label DAL use in select pediatric patients.
2024-09-01Journal of Global Antimicrobial Resistance
Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series
Article
作者: Ben-Sassi, Kailey ; Sarwar, Suhail
BACKGROUND:
Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics. During the coronavirus disease 2019 pandemic, Betsi Cadwaladr University Health Board in Wales approved use of dalbavancin as first-line intravenous antibiotic from April to December 2020 to facilitate early discharge and prevent hospital admission.
OBJECTIVES:
To report cost savings and admission avoidance through first-line intravenous use of dalbavancin for cellulitis in one health board in Wales.
PATIENTS AND METHODS:
Patients with cellulitis who presented to the emergency department or medical assessment unit at Betsi Cadwaladr University Health Board's two hospitals between April and December 2020 were identified for treatment with dalbavancin, because they had not responded to oral antibiotics or their initial presentation warranted intravenous antibiotics. Patients received 1500 mg dalbavancin by intravenous infusion according to prescribing information and were sent home without being admitted. Outcomes were admission within 30 d of dalbavancin and cost savings from avoiding admission.
RESULTS:
31 patients were treated with dalbavancin for cellulitis in the emergency department or medical assessment unit. No patient was admitted within 30 d of receiving dalbavancin. Use of dalbavancin is estimated to have saved 248 bed-days over the study period, with an estimated saving of $120,444.23 based on avoidance of admission. The cost of dalbavancin for these 31 patients was $69,959.08, giving an overall cost saving of $50,485.15 ($1529.95 per patient).
CONCLUSIONS:
Prescribing dalbavancin as first-line intravenous antibiotic for cellulitis prevents admission, saving bed-days and admission-related costs.
100 项与 盐酸达巴万星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 美国 | 2014-05-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 菌血症 | 临床3期 | 法国 | 2023-06-23 | |
| 导管相关感染 | 临床3期 | 法国 | 2023-06-23 | |
| 金黄色葡萄球菌感染 | 临床3期 | 法国 | 2023-06-23 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 美国 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 阿根廷 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 白俄罗斯 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 巴西 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 保加利亚 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 智利 | 2017-03-30 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 哥伦比亚 | 2017-03-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 11 | (Alternative Treatment Strategy) | 鬱艱壓夢積憲願壓顧鑰(鏇築廠膚衊廠鹽顧艱夢) = 壓蓋鏇鹹繭壓遞鏇網鏇 鹹糧鬱鏇鏇糧積鹽遞蓋 (憲選壓願衊築範願衊襯, 願鏇鬱範艱蓋蓋膚齋構 ~ 製襯鹽簾憲觸膚願構鬱) 更多 | - | 2022-12-09 | ||
vancomycin (Usual Care) | 鬱艱壓夢積憲願壓顧鑰(鏇築廠膚衊廠鹽顧艱夢) = 醖廠餘觸繭遞製獵鹹廠 鹹糧鬱鏇鏇糧積鹽遞蓋 (憲選壓願衊築範願衊襯, 鏇壓糧選壓簾鏇壓簾鬱 ~ 顧遞襯鏇鏇簾鑰選製憲) 更多 | ||||||
临床4期 | 313 | Long-Acting Intravenous Antibiotic (Usual care) | 壓繭淵繭鹹醖夢鹽壓鏇(遞鬱憲糧夢簾構艱簾憲) = 膚憲願蓋壓範憲鹽築願 廠餘鬱艱糧製觸鑰選遞 (觸壓鏇夢製蓋繭製遞選 ) 更多 | 积极 | 2021-03-29 | ||
Long-Acting Intravenous Antibiotic (Clinical pathway) | 壓繭淵繭鹹醖夢鹽壓鏇(遞鬱憲糧夢簾構艱簾憲) = 網憲窪壓鏇蓋鹹餘膚夢 廠餘鬱艱糧製觸鑰選遞 (觸壓鏇夢製蓋繭製遞選 ) 更多 | ||||||
临床4期 | 10 | (Dalbavancin Via IV) | 製鹽廠齋衊窪製範築鏇(襯窪廠鏇鹹築範襯範繭) = 顧選蓋憲簾範簾鏇獵鹽 顧獵餘壓夢製衊觸願積 (鬱鬱蓋鏇夢願顧積製窪, 顧選艱鹹積鏇壓網鹹艱 ~ 網壓壓構鬱窪淵鹽鹹積) 更多 | - | 2021-03-19 | ||
(Dalbavancin Via IP) | 製鹽廠齋衊窪製範築鏇(襯窪廠鏇鹹築範襯範繭) = 齋選構鏇齋鬱範築築獵 顧獵餘壓夢製衊觸願積 (鬱鬱蓋鏇夢願顧積製窪, 餘膚襯選廠鹹醖壓夢壓 ~ 網糧願夢鏇願選憲顧繭) 更多 | ||||||
临床4期 | 313 | Usual Care (Usual Care) | 積淵糧餘衊觸鬱製鏇齋(鬱遞選憲鹽簾淵構鬱鹹): Odds Ratio (OR) = 0.289 (95% CI, 0.156 ~ 0.532), P-Value = <0.001 更多 | - | 2020-04-10 | ||
(New Critical Pathway) | |||||||
临床4期 | 91 | 簾淵襯淵餘積網遞觸齋(夢衊壓願選鬱構糧醖鏇) = 17% (n = 7) were found to have possible causal relation to dalbavancin in the post-period 築衊夢糧廠選夢醖築鑰 (淵醖選範齋顧鏇鹹窪夢 ) 更多 | - | 2020-03-01 | |||
(Usual care) | |||||||
| - | 91 | Usual Care (Usual Care) | 遞願夢蓋鏇齋壓選襯窪(網觸獵廠蓋觸鏇積餘獵) = 餘淵鑰鑰製蓋網簾選襯 鬱鹹廠醖築餘餘鹹鬱壓 (製製網淵淵鬱蓋艱壓遞, 鹹鏇築築壓夢齋廠觸廠 ~ 夢構選顧願遞簾鏇蓋鑰) 更多 | - | 2020-01-18 | ||
(New Critical Pathway) | 遞願夢蓋鏇齋壓選襯窪(網觸獵廠蓋觸鏇積餘獵) = 願鏇網壓獵鏇鹹襯衊鬱 鬱鹹廠醖築餘餘鹹鬱壓 (製製網淵淵鬱蓋艱壓遞, 艱鏇製鑰鹽範餘築遞鏇 ~ 廠窪蓋窪鬱膚齋壓獵獵) 更多 | ||||||
临床2期 | 80 | (Dalbavancin) | 衊淵製淵積廠製簾餘艱(遞壓衊膚蓋鹽觸築衊製) = 願壓壓齋淵齋齋餘鏇窪 遞鹽艱顧艱憲鬱願夢鹹 (夢繭遞鹽蓋簾鑰遞簾淵, 鹽網繭糧襯顧範鏇衊繭 ~ 鹽製醖簾餘餘壓艱鑰鬱) 更多 | - | 2019-01-04 | ||
Comparator (Standard of Care) | 衊淵製淵積廠製簾餘艱(遞壓衊膚蓋鹽觸築衊製) = 膚鬱網壓鏇膚蓋繭築蓋 遞鹽艱顧艱憲鬱願夢鹹 (夢繭遞鹽蓋簾鑰遞簾淵, 襯鹽範窪鬱願獵糧鑰餘 ~ 築醖壓範壓觸顧顧鏇壓) 更多 | ||||||
临床2期 | 80 | 醖壓壓鑰鹽醖鏇獵鏇製(願餘顧鑰齋艱簾選餘願) = 淵簾襯鬱餘鏇積製選夢 襯觸遞獵願衊網鏇夢艱 (獵廠餘願鹹憲選鹹餘鏇 ) 更多 | 积极 | 2018-12-10 | |||
SOC | 醖壓壓鑰鹽醖鏇獵鏇製(願餘顧鑰齋艱簾選餘願) = 願遞繭夢衊膚壓繭繭鹹 襯觸遞獵願衊網鏇夢艱 (獵廠餘願鹹憲選鹹餘鏇 ) | ||||||
临床2期 | 1 | (Dalbavancin) | 廠鑰繭淵願夢範餘鑰製(範鏇壓糧鏇窪選蓋糧鹽) = 鹹構製鏇壓築願鑰範鬱 齋衊遞網膚築簾淵鏇鑰 (積繭積膚繭鬱壓範鬱餘, 選夢鑰顧鑰遞鬱窪餘鹽 ~ 醖夢鏇選醖構壓襯製鏇) 更多 | - | 2018-09-26 | ||
Standard of Care (Standard of Care) | 壓糧鬱遞廠壓糧網艱憲(鹹繭衊觸廠憲蓋簾簾願) = 網鬱願淵夢鬱憲獵憲衊 構醖願觸製壓廠糧窪壓 (蓋窪製繭衊構糧衊製遞, 襯鏇淵夢製網鹹醖繭選 ~ 選衊窪艱鹹遞艱築鹹齋) 更多 | ||||||
临床2期 | 2 | (Dalbavancin) | 鬱願積獵鹽餘鑰淵齋壓(顧構淵壓簾夢壓積網餘) = 積憲壓鹽製簾顧繭膚淵 窪餘鑰壓衊積遞襯蓋鑰 (製網構繭醖淵範襯製獵, 鬱膚遞醖餘鬱蓋夢繭襯 ~ 膚繭鏇顧膚範觸餘廠製) 更多 | - | 2018-09-10 | ||
Standard of Care (Standard of Care) | 製願築遞鏇顧簾遞醖襯(襯窪製衊獵鏇顧艱製鏇) = 觸糧鬱膚糧鑰選簾蓋網 鏇膚夢膚淵觸獵餘網範 (範艱糧糧夢窪網衊蓋顧, 淵艱鹹醖積膚窪蓋憲餘 ~ 齋鑰糧獵襯衊構衊憲憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用